Alzheimer's and Psilocybin

The Brain They Said Was Already Gone

There is a particular kind of cruelty to Alzheimer’s disease. I’ve watched it closely as it took away the person that once was my brother. It does not kill you all at once. It takes the person first, slowly and methodically, leaving the body behind to carry on without them. Decades of pharmaceutical research have produced drugs that can, at best, slow the forgetting by a few months. Nothing stops it. Nothing reverses it. The standard line from neurologists has long been that once the damage is done, it is done.

A growing number of researchers now believe that line may be wrong. And the compounds they are pointing to as evidence are the same ones that spent the better part of fifty years classified as Schedule I substances with no accepted medical use. They are psilocybin, LSD, and their chemical relatives, the psychedelics.

This is not fringe science as the research is being conducted at Johns Hopkins, published in peer-reviewed journals like Frontiers in Neuroscience, and funded through legitimate academic channels. In 2024, a team of researchers published a detailed analysis of psilocybin’s potential as an Alzheimer’s treatment. What they found was not a marginal effect. They found something that looked, at the molecular level, like a direct assault on the mechanisms that drive the disease.

What Psilocybin Actually Does to the Brain

Alzheimer’s is a story of structural collapse. The brain loses its ability to build and maintain connections. Dendritic spines, those the tiny protrusions on neurons that receive signals from neighboring cells, wither and disappear. Synaptic proteins break down. The architecture of memory and personality is dismantled, piece by piece, over years.

Psilocybin appears to do the opposite. Studies on cortical neurons have shown that even low doses of psilocybin and LSD significantly increase the complexity of dendritic branching and raise the density of dendritic spines. The drugs stimulate the brain to rebuild the very structures Alzheimer’s tears down. The mechanism runs through a receptor called TrkB which is the primary receptor for a protein called BDNF. Psychedelics bind to TrkB with roughly one thousand times greater affinity than standard antidepressants.

This is why a single supervised dose of psilocybin appears to produce measurable neurological changes that can persist for months or more. This is not how conventional medicine works. Conventional medicine requires daily dosing to maintain effect. What researchers are seeing with psychedelics is closer to a reset.

The Fire That Destroys the Brain From the Inside

There is a second front in this story, and it may be even more important than the neuroplasticity findings. Neuroinflammation, the chronic, low-grade immune activation in the brain, is now understood to be a central driver of Alzheimer’s progression. The brain’s immune cells, microglia, go haywire. They stop cleaning up cellular debris and start attacking healthy tissue. Inflammatory chemicals called cytokines flood the environment. These are the markers of a system that will not stand down.

Laboratory studies have found that psilocybin-related compounds can suppress the production of each of those inflammatory markers. Simultaneously, they appear to reduce levels of APAF-1, a protein involved in triggering neuron death, while upregulating neuroprotective factors including BDNF and GDNF. The same drug that rebuilds the brain’s architecture appears to also douse the fire that is consuming it. That dual action is something the pharmaceutical industry has been chasing for decades with conventional compounds and has not achieved.

The Trials That Are Actually Happening

Johns Hopkins is running a pilot study, registered as NCT04123314 with the U.S. government, specifically testing psilocybin in patients with mild cognitive impairment or early-stage Alzheimer’s disease. The initial focus is depression, which affects up to forty percent of Alzheimer’s patients, accelerates cognitive decline, and has no good treatment options within that population. If psilocybin can address both the mood disorder and the underlying neurological damage in the same session, that is not an incremental advance. That is a different category of medicine.

A 2025 paper in Frontiers in Dementia pushed the research further in an unexpected direction. Researchers exposed human brain organoids, those miniature structures grown from human stem cells that mimic the architecture of a developing brain, to psychedelic compounds, then analyzed protein related response. The early results pointed to specific molecular pathways where psychedelics appear to be most active, providing a roadmap for more targeted clinical investigation. The science is moving faster than most people realize.

What Is Actually Standing in the Way

Psilocybin is still a Schedule I controlled substance in the United States. That classification was not based on scientific evidence of harm. It was a political decision, made in 1970 under the Controlled Substances Act, and it has never been revisited in any serious formal way. The FDA has granted psilocybin Breakthrough Therapy designation for treatment-resistant depression but no approval covering neurodegeneration has been sought.

There are also practical challenges that honest researchers acknowledge openly. Alzheimer’s patients, particularly those in moderate or late stages, may be vulnerable to the disorienting perceptual effects that these compounds produce. Running a safe, supervised psychedelic session requires trained guides, controlled environments, and hours of preparation and integration. Scaling that to the tens of millions of people affected by the disease is a problem that nobody has solved. For now, the trials are small, the sample sizes are modest, and the findings remain preliminary.

A Different Kind of Reckoning

The history of psychedelics and the history of Alzheimer’s research have, until recently, been entirely separate stories. One was the story of counterculture, of Leary and McKenna and the DEA and the war on drugs. The other was the story of pharmaceutical failure, of billions of dollars spent chasing amyloid plaques with compounds that worked beautifully in mice and did almost nothing in humans.

Those two stories are now converging. The same cultural suppression that pushed psychedelics underground for fifty years also delayed by decades the scientific investigation of what these compounds actually do to the brain. We are only now beginning to find out. And what we are finding out, according to a growing body of research from serious institutions, is that the brain they said was already gone might not be as far gone as anyone thought.

Psychedelics do not just represent a new drug for an old disease. They represent a challenge to the entire framework through which we have been trying to understand and treat neurodegeneration. The silent architects of that challenge are not distributors or chemists or countercultural icons. They are researchers working in universities and publishing papers that almost nobody outside the field is reading.

The brain they said was already gone, may still have something left to say.